The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer.
Following on from an update from the company, the timelines for this appraisal remain to be confirmed.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties as and when the situation changes.